ClinicalTrials.gg
TerminatedNCT06652958Updated Oct 15, 2026

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

A Phase 1 interventional study of VH4527079 in HIV Infections, sponsored by ViiV Healthcare. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Terminated for business reasons
Updated Oct 15, 2026Now TerminatedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
159th of 210
30 · median 82
Started
2024
with 10 others
Phase 1
83 of 266
9 open now
Registered
249th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 159th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 83 in phase 1, and was the 249th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).

03

Conditions studied

  • HIV Infections

Keywords

  • Human Immunodeficiency Virus (HIV)
  • VH4527079
  • Monoclonal Antibody
  • Safety
  • Pharmacokinetics (PK)
  • Healthy Adults
  • Persons with HIV (PWH)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive at the time of signing the .
  • Participants who are overtly healthy based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
  • For Cohort 9 (PWH in Arm B), well controlled on INSTI-based oral antiretroviral therapy without history of virologic failure (will be continued during study).
  • Body weight more than or equal to (>=)50.0 kg for men and >=45.0 kg for women and (BMI) within the range 18.5 to 31.0 kg/m\^2.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    • Participants who are female at birth are eligible to participate if at least one of the following conditions applies: Not pregnant or breastfeeding and, at least, one of the following conditions apply:

      • Is not a Participant of (POCBP). OR
      • Is a POCBP and agrees to use a highly effective contraceptive method 3 weeks prior to the start of this study and during the study.
  • Capable of giving signed informed consent.
  • Willing to have samples stored for future research for participants in Arm B; Cohort 8 (Healthy Volunteers) and Cohort 9 (PWH in Arm B).

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders, or any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Weight >115.0 kg.
  • Any medical condition that is not well controlled.
  • Positive testing for participants enrolled in Arm A and in Arm B Cohort 8.
  • Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk of recurrence during the study.
  • The participant has an underlying skin disease or disorder, piercing, or tattoos that would interfere with assessment of injection site reactions.
  • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy.
  • multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions.
  • Any condition which, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to take oral medication.
  • Unstable liver disease, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease).
  • Known history of cirrhosis with or without viral hepatitis co-infection.
  • History of clinically relevant hepatitis within last 6 months.
  • For Cohort 9 (PWH in Arm B), untreated syphilis infection (i.e., positive syphilis testing at screening) without documentation of treatment. Participants who have successfully completed treatment at least 7 days previously are eligible if recruitment is open. Positive syphilis testing at screening for any other Cohort is exclusionary.
  • Lymphoma, leukemia, or any (except for breast cancer) within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Participants who poses a significant suicidality risk.
  • Any pre-existing physical or mental condition which, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
  • Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long syndrome or sudden cardiac death. Any significant arrhythmia or finding which, will interfere with the safety for the individual participant.
  • Exposure to an experimental drug, human blood product, anticoagulants, or experimental vaccine (which does not have emergency, conditional, or standard market authorization) within 30 days, or within 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention or plans to receive during the study.
  • Any previous use of HIV Pre-exposure prophylaxis (PrEP) or Post-exposure prophylaxis (PEP) in Arm A (Cohorts 1 through 7) or Arm B (Cohort 8 only), either oral or parenteral, is exclusionary.
  • Any previous use of Neonatal Fc receptor blockers (e.g., efgartigimod alfa-fcab).
  • The participant has ever received an HIV vaccine.
  • Any approved or experimental non-HIV vaccination (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), virus (HBV), influenza, pneumococcal polysaccharide) received within 2 weeks prior to study enrollment (Day 0).
  • Exposure to an experimental drug, human blood product, or vaccine (which does not have emergency, conditional, or standard market authorization) within 28 days prior to the first dose of study treatment or plans to receive live vaccines during the study.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • Exposure to more than 4 new chemical entities or vaccines within 12 months prior to the first dosing day.
  • Past or intended use of over-the-counter or prescription medication including herbal medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing.
  • Participants who require concomitant medications known to be associated with a prolonged QTc.
  • Participants receiving any protocol-prohibited medication(s) and who are unwilling or unable to switch to an alternate medication.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Arm A, Cohort 1

    Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 2

    Healthy adult participants receive a single dose of VH4527079 Dose 2 (low dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 3

    Healthy adult participants receive a single dose of VH4527079 Dose 3 (mid-low dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 4

    Healthy adult participants receive a single dose of VH4527079 Dose 4 (mid-high dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 5

    Healthy adult participants receive a single dose of VH4527079 Dose 5 (high dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 6

    Healthy adult participants receive a single dose of VH4527079 Dose 6 (max dose) by IV infusion.

    Biological: VH4527079

  • Experimental
    Arm A, Cohort 7

    Healthy adult participants receive a single dose of VH4527079 Dose 1 (lowest dose) by SC injection.

    Biological: VH4527079

  • Experimental
    Arm B, Cohort 8

    Healthy adult participants receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.

    Biological: VH4527079

  • Experimental
    Arm B, Cohort 9

    Participants with HIV receive three doses of VH4527079 dose that is selected in Arm A, by IV infusion, separated by a time interval.

    Biological: VH4527079

Interventions

  • BiologicalVH4527079

    VH4527079 solution for injection or infusion will be administered either by SC injection or IV infusion respectively.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) of Grade 2 and above severity

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of AEs will be assessed using Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life threatening and Grade 5=Death.

    Time frame: Up to Week 24 follow-up period

  2. Area under the plasma-concentration time curve from time zero to infinity (AUC 0-inf) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

  3. Area under the plasma-concentration time curve from time zero to the last quantifiable concentration (AUC 0-tlast) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

  4. Area under the plasma-concentration time curve from defined interval between doses (AUCtau) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

  5. Maximum observed plasma concentration (Cmax) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

  6. Time to maximum observed plasma concentration (Tmax) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

  7. Apparent terminal half-life (t1/2) of VH4527079

    Time frame: From Day 1 Up to Week 24 follow-up period

Secondary outcomes

  1. AUC0-inf of VH4527079 after a single dose administered via SC route relative to IV administration

    Time frame: From Day 1 Up to Week 24 follow-up period

  2. AUC0-tlast of VH4527079 after a single dose administered via SC route relative to IV administration

    Time frame: From Day 1 Up to Week 24 follow-up period

  3. Cmax of VH4527079 after a single dose administered via SC route relative to IV administration

    Time frame: From Day 1 Up to Week 24 follow-up period

  4. Post-baseline values for chemistry panels: Glucose (fasting), Blood Urea Nitrogen, Creatinine, Calcium, Magnesium, Potassium, Phosphate, Direct Bilirubin, Total Bilirubin & Fasting lipid panel (milligrams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  5. Post-baseline values for chemistry panels: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)

    Chemistry panels included Aspartate aminotransferase (AST)/ Serum glutamic-oxalo-acetic transaminase (SGOT), Alanine aminotransferase (ALT)/ Serum glutamic-pyruvic transaminase (SGPT), Alkaline phosphatase (ALP) and Creatinine phosphokinase (CPK)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  6. Post-baseline values for chemistry panels: Amylase and Lipase (fasting) (Units per Liter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  7. Post-baseline values for chemistry panels: Total Protein (Grams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  8. Post-baseline values for chemistry panels: Sodium chloride and Bicarbonate (milliequivalents per liter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  9. Post-baseline values for hematology panels: Platelet count (cells per microliter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  10. Post-baseline values for hematology panels: Red Blood Cell (RBC) Count (million cells per microliter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  11. Post-baseline values for hematology panels: Hemoglobin (Hgb) (grams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  12. Post-baseline values for hematology panels: Hematocrit (Proportion of red blood cells in blood)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  13. Post-baseline values for hematology panels: Mean Corpuscular Volume (MCV) (Femtoliters)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  14. Post-baseline values for hematology panels: Mean Corpuscular Hemoglobin (MCH) (Picograms)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  15. Post-baseline values for hematology panels: Reticulocytes (Percentage of reticulocytes)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  16. Post-baseline values for hematology panels: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  17. Post-baseline values for coagulation panels: Prothrombin time (PT) and Partial Thromboplastin Time (PTT) (Seconds)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  18. Post-baseline values for coagulation panels: International normalized ratio (INR) (Ratio)

    Time frame: From Day 1 (pre-Dose 1) Up to Week 24 follow-up period

  19. Change from baseline values for chemistry panels: Glucose (fasting), Blood Urea Nitrogen, Creatinine, Calcium, Magnesium, Potassium, Phosphate, Direct Bilirubin, Total Bilirubin and Fasting lipid panel (milligrams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  20. Change from baseline values for chemistry panels: AST/ SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  21. Change from baseline values for chemistry panels: Amylase and Lipase (fasting) (Units per Liter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  22. Change from baseline values for chemistry panels: Total Protein (Grams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  23. Change from baseline values for chemistry panels: Sodium chloride and Bicarbonate (milliequivalents per liter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  24. Change from baseline values for hematology panels: Platelet count (cells per microliter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  25. Change from baseline values for hematology panels: RBC Count (million cells per microliter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  26. Change from baseline values for hematology panels: Hgb (grams per deciliter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  27. Change from baseline values for hematology panels: Hematocrit (Proportion of red blood cells in blood)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  28. Change from baseline values for hematology panels: MCV (Femtoliters)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  29. Change from baseline values for hematology panels: MCH (Picograms)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  30. Change from baseline values for hematology panels: Reticulocytes (Percentage of reticulocytes)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  31. Change from baseline values for hematology panels: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  32. Change from baseline values for coagulation panels: PT and PTT (Seconds)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  33. Change from baseline values for coagulation panels: INR (Ratio)

    Time frame: From Day 1 (pre-Dose 1) up to Week 24 follow-up period

  34. Number of participants with maximum post-baseline QT interval corrected (QTc) values compared to baseline by category

    QTc values will be categorized as no change= number of participants with QTc values less than or equal to (\<=)450 milliseconds (msec), any increase= number of participants with QTc values more than (\>)450 - 480 msec, number of participants with QTc values \>480 -500 msec, and number of participants with QTc values \>500 msec

    Time frame: Up to Week 24 follow-up period

  35. Number of participants with maximum post-baseline increases in QTc values compared to baseline by category

    Post-baseline increase in QTc values will be categorized by number of participants with QTc value increase of \<=30 msec, number of participants with QTc value increase of 31 - 60 msec, and number of participants with QTc value increase of \>60 msec

    Time frame: Up to Week 24 follow-up period

  36. Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic and systolic blood pressure

    Number of participants with post-baseline changes will be categorized as change to low, change to within range or no change, and change to high

    Time frame: Up to Week 24 follow-up period

  37. Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for pulse rate

    Number of participants with post-baseline changes will be categorized as change to low, change to within range or no change, and change to high

    Time frame: Up to Week 24 follow-up period

  38. Number of participants with any AEs and AEs by severity

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity of AEs will be assessed using Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life threatening and Grade 5=Death.

    Time frame: Up to Week 24 follow-up period

  39. Number of participants who discontinue treatment due to AEs

    Time frame: Up to Week 24 follow-up period

07

Study locations

1 site
  • GSK Investigational Site
    Las Vegas, Nevada 89113-2235, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Sep 2026, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2024
First posted
Oct 22, 2024
StartActual
Oct 2, 2024
Primary completionActual
Sep 9, 2026
CompletionActual
Sep 9, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Terminated for business reasons
changed Oct 15, 2026
Sites
1 site removed
Show 1 removed
  • GSK Investigational Site · Austin, United States
Oct 15, 2026
Enrollment
102 (estimated)→30 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Terminated
    Why stopped Terminated for business reasons
    1 site removed
    Show 1 removed
    • GSK Investigational Site · Austin, United States
    Enrollment 102 (estimated)→30 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06652958
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Oct 2, 2024
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion